Group One Trading’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-15,100
| Closed | -$580K | – | 8619 |
|
|
2023
Q2 | $580K | Buy |
15,100
+7,200
| +91% | +$185K | ﹤0.01% | 2866 |
|
|
2023
Q1 | $183K | Buy |
+7,900
| New | +$188K | ﹤0.01% | 3762 |
|
|
2022
Q1 | – | Sell |
-100
| Closed | -$2K | – | 8985 |
|
|
2021
Q4 | $2K | Buy |
+100
| New | +$1.42K | ﹤0.01% | 7933 |
|
|
2019
Q4 | – | Sell |
-320
| Closed | -$2K | – | 5780 |
|
|
2019
Q3 | $2K | Hold |
320
| – | – | ﹤0.01% | 4940 |
|
|
2019
Q2 | $2K | Buy |
+320
| New | +$4.87K | ﹤0.01% | 4781 |
|
|
2019
Q1 | – | Sell |
-220
| Closed | -$3K | – | 5517 |
|
|
2018
Q4 | $3K | Buy |
220
+20
| +10% | +$400 | ﹤0.01% | 4610 |
|
|
2018
Q3 | $7K | Sell |
200
-60
| -23% | -$1.93K | ﹤0.01% | 4762 |
|
|
2018
Q2 | $9K | Buy |
260
+200
| +333% | +$7.67K | ﹤0.01% | 4664 |
|
|
2018
Q1 | $3K | Sell |
60
-1,940
| -97% | -$71K | ﹤0.01% | 4608 |
|
|
2017
Q4 | $75K | Buy |
+2,000
| New | +$87.3K | ﹤0.01% | 3525 |
|
|
2016
Q4 | – | Sell |
-200
| Closed | -$12K | – | 4949 |
|
|
2016
Q3 | $12K | Sell |
200
-6,000
| -97% | -$424K | ﹤0.01% | 3998 |
|
|
2016
Q2 | $351K | Buy |
6,200
+4,440
| +252% | +$270K | ﹤0.01% | 1993 |
|
|
2016
Q1 | $113K | Sell |
1,760
-2,140
| -55% | -$173K | ﹤0.01% | 2745 |
|
|
2015
Q4 | $549K | Buy |
3,900
+2,700
| +225% | +$367K | 0.01% | 1752 |
|
|
2015
Q3 | $116K | Buy |
+1,200
| New | +$143K | ﹤0.01% | 2942 |
|
Group One Trading's KDNY Position: Q4 2022 in Review
Group One Trading sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2022, closing a stake of 2,600 shares — an estimated $57.6K sold.
Group One Trading first reported a position in KDNY in Q3 2015 and held it in 15 quarters. The position peaked at $262K in Q1 2016. 155 funds tracked by Wall St. Rank hold KDNY as of Q4 2022.
- Group One Trading reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Group One Trading sold 2,600 Chinook Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $57.6K.
- Group One Trading first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2015 and held it in 15 quarters.
- Group One Trading's Chinook Therapeutics, Inc. Common Stock position peaked at $262K in Q1 2016.
- 155 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Group One Trading's 13F filing for Q4 2022, filed 9 Feb 2023.